ResultsIQ

ResultsIQ › Latest results › Acutaas Chemicals Limited

Acutaas Chemicals Limited Q1 FY26 results deck summary

NSE: ACUTAAS · BSE: 543349

Results deck of 30 Jul 2025, summarised by AI from the filing.

Acutaas Chemicals Q1 FY26 revenue ₹2,072 cr, up 17.3% year-on-year, with FY26 guidance of 25% growth and improved margins.

Key takeaways

  1. Q1 FY26 revenue Revenue from operations was ₹2,072 cr, up 17.3% year-on-year from ₹1,767 cr in Q1 FY25.
  2. FY26 guidance Management guides 25% growth with improved margins for FY26.
  3. PAT growth PAT rose to ₹440 cr in Q1 FY26 from ₹147 cr in Q1 FY25, a 199.6% increase.
  4. Pharma intermediates Robust growth in Advanced Pharmaceutical Intermediates supported overall revenue, with specialty chemicals steady.

Original filing on BSE

Acutaas Chemicals Limited Q1 FY27 results

As filed: Revenue ₹330 cr (+59% year on year), EBITDA ₹113 cr (+122% year on year), PAT ₹75.0 cr (+70% year on year), EBITDA margin 34.3% (+966 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹422 cr, EBITDA ₹181 cr, PAT ₹137 cr, EBITDA margin 43.0%. Not scored. No result for the same quarter last year. Share price after the results: +25.2% in 29 days (Nifty 500: −0.9%).
  • Q3 FY26: Revenue ₹391 cr, EBITDA ₹154 cr, PAT ₹112 cr, EBITDA margin 39.5%. Not scored. No result for the same quarter last year. Share price after the results: +30.9% in 30 days (Nifty 500: +1.5%).
  • Q2 FY26: Revenue ₹305 cr, EBITDA ₹97.0 cr, PAT ₹73.0 cr, EBITDA margin 31.8%. Not scored. No result for the same quarter last year. Share price after the results: +10.2% in 28 days (Nifty 500: +1.2%).
  • Q1 FY26: Revenue ₹206 cr, EBITDA ₹51.0 cr, PAT ₹45.0 cr, EBITDA margin 24.8%. Not scored. No result for the same quarter last year. Share price after the results: +20.5% in 30 days (Nifty 500: −2.4%).

Past price moves after results do not indicate future moves. Not a recommendation.

Acutaas Chemicals Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.